The promise of adoptive cell therapy | Peter Attia, M.D. & Steven Rosenberg, M.D., Ph.D.

Well SupportedCommon epithelial cancers have low reactivity to checkpoint modulators due to insufficient mutagenic burden.

Partially SupportedImmunotherapy has demonstrated efficacy in treating liver tumors, bile duct cancers, breast cancer, colon cancer, cervical cancer, and ovarian cancer.

Partially SupportedLymphocytes can be genetically modified to recognize and attack cancer cells by giving them receptors for specific antigens.

Partially SupportedT cells can be engineered to target antigens present on 80% of common cancers, leading to tumor regressions.